Loading…
Loading…
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company's patent application covering the intended commercial formulation of ART27.13, Artelo's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company's peripherally selective cannabinoid agonist currently being evaluated in the Phase 2 CAReS trial for cancer-related anorexia and the Phase 2 DREAM study in patients with glaucoma or ocular hypertension.
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the second quarter ended June 30, 2026.
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels SOLANA BEACH, Calif.
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer